Research Centre: University of Adelaide
Location: Clinical Research Facility, Level 4, Adelaide Health and Medical Sciences Building, Corner North Tce and George St Adelaide SA 5005
Lead Researcher: Professor Karen Jones
HREC: This study has been reviewed and approved by the Central Area Local Health Network Human Research Ethics Committee (CALHN HREC) and the University of Adelaide

Could a weekly medication impact both blood sugar and blood pressure in people living with type 2 diabetes? This study investigates the effect of a drug, Semagultide (also known as Ozempic®), widely used in the management of type 2 diabetes and for weight loss, on the rate at which the stomach empties and its connection to blood sugar levels and changes in blood pressure.

Researchers want to find out how long these effects continue after stopping the treatment. This study will provide important information that will improve the care of people living with type 2 diabetes around the world.

Interested? See if you qualify for this study!

• Participants will receive an approved treatment for type 2 diabetes at no cost.
• Participants will receive up to $670 as an honorarium for the time spent participating in this study.
• Participants may experience improvements in their blood sugar and weight loss.
• Participants will be contributing valuable information about the drug, semaglutide, used in the management of type 2 diabetes and its potential to reduce a fall in blood pressure after a meal, often experienced in people living with type 2 diabetes.
• Participants will be helping to advance medical research.
• Participants will have access to advanced medical imaging technology
• Participants will contribute to potentially improve treatment for postprandial hypotension and gastric emptying disorders
• Participants will be part of a study led by a globally recognized research team, committed to making a real world impact.

• If you decide to participate in the study and later feel that you no longer wish to be part of it, you can withdraw at any time.
• Any information that you provide will be kept strictly confidential, except as required by law.
• Qualified health professionals will monitor your health as it relates to the study.

• Men and women aged 40 – 80 who are diagnosed with type 2 diabetes
• Must have a BMI of 25 – 40 kg/m2
• Must be managing their type 2 diabetes by diet alone or metformin only
• Must be postmenopausal or pre-menopausal with surgical contraception or an intrauterine device
• Must not be pregnant or breastfeeding
• Must not be vegetarian or vegan
• Must be able and willing to participate in the study for approximately 16 weeks after enrolment with weekly visits for 13 weeks

The study team will explain the research in its entirety, however, some broad details include:

• Participants will be asked to attend a screening visit at the clinical research facility after an overnight fast to review medical history, record height and weight, and complete standardised questionnaires on gastrointestinal symptoms.
• Participants will undergo study visits, where they will have their rate of stomach emptying, blood sugar and gut hormone levels, and blood pressure measured for approximately 5-6 hours, on day 1 (before treatment), 12 weeks after treatment, and 1 and 4 weeks (after stopping the treatment).
• Participants will be asked to attend weekly laboratory visits during the 11-week intervention period in which placebo or semaglutide (Ozempic®) (doses gradually increasing from 0.25 mg to 1 mg) will be administered via subcutaneous injection.
• Participants will be asked to participate in a follow-up telephone call 4 weeks after the final visit to assess their well-being and report any adverse effects.

University of Adelaide
The Centre of Research Excellence (CRE) in Translating Nutritional Science to Good Health was established in 2012.

Initially funded by the National Health and Medical Research Council (NHMRC), the CRE seeks to encourage and promote clinical research in the area of nutritional physiology.

The Centre aims to formalise existing collaborations and facilitate the development of others, which span the spectrum from basic science, through human physiology and clinical medicine, to population health.

Our investigators, with backgrounds in endocrinology, gastroenterology, nutritional science, nuclear medicine, physiology, epidemiology and nursing, bring unique technical skills, unparalleled in this country, and a sustained record of productivity in clinical nutritional research, attested to by a high international profile, substantial impact on clinical practice, and the capacity to communicate a healthy nutrition philosophy to the public.